Here are some key insights to help unlock the viability of PDTs to address unmet needs throughout the healthcare ecosystem — for patients and providers alike — and how to take meaningful steps to improve the health experience.
To identify true growth opportunities, investors must consider how companies are using AI to revolutionize the treatment journey. Some companies are doing just that via Software as a Medical Device (SaMD), particularly by developing prescription digital therapeutics (PDTs).
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.